ATM and non-small cell lung carcinoma: A total of 191 NSCLC patients with pathogenic or likely pathogenic ATM/ATR mutations (denoted as “PIKK-mutated”) were included in the study cohort, and only one patient (P145) harbored both ATM and ATR pathogenic mutations (Additional file 1: Table S1).